Table 2 General features of dermatomyositis from the present study and literature

Current study

Bohan & Peter, and EULAR/ACR

PM/Scl(+)

G, H, MH

MW, ENMG, Lab

Yes

Yes

-

AZA, MTX

MMF 1 g/day

CCR

MDA-5(+)

G, H, CA, RP

-

-

-

Yes

AZA

MTX 25 mg/week

CCR

PM/Scl(+)

G, H, RP, MH

MW, Lab

Yes

Yes

Yes

AZA, CP, MTX

MMF 1.44 g/day

CCR

All negative*

G, H, CA

MW, ENMG, Bx, Lab

Yes

-

Yes

AZA, CP

MTX 15 mg/week, MMF 1 g/day

Remission

Ro-52(+), PM/Scl(+)

G, H, RP, MH

MW, ENMG, Bx

Yes

Yes

Yes

AZA, MTX

-

Remission

MDA-5(+)

G, H

-

-

Yes

Yes

AZA, CP. MMF, RITUX

MTX 20 mg/week

CCR

All negative*

G, H

MW, ENMG, Bx, Lab

Yes

-

Yes

MTX

Aza 150 mg/day

GC 40 mg/day

Remission

MDA-5(+)

G, H

MW

-

Yes

-

AZA, CP, MMF, MTX, RITUX

-

Remission

Jo(+)

G, RP, MH

MW, ENMG, Bx,

Yes

Yes

Yes

-

MMF 2 g/day, MTX 12.5 mg/week

Remission

Chu et al. [6]

Bohan & Peter

Cut, Musc

MSA(-)

G, H, VS, SP

MW, Bx, ENMG

-

-

-

MTX, MP, HCQ

MP 8 mg/day, HCQ 200 mg/day, MTX 5 mg/week

Activity

Xu et al. [7]

Cut, Musc

ANA(+)

H, VS, SS, PRSL

MW, Bx

-

Yes

Yes

ADA

Upadacitinib 15 mg/day

Controlled

Perna et al. [8]

Cut, Musc

N/A

G, H, VS, VEP

MW, Bx

-

-

Yes

MTX

MTX

Activity

Schreiber et al. [9]

Cut, Musc

Jo(+), AMA(+), AML(+), ANA(-), CCP(-)

MH

MW, MRI, Bx

-

-

Yes

AZA, MTX, MMF

MTX 20 mg/week

Controlled

Markovic et al. [10]

EULAR/ACR

ANA(+)

G, H, SP, VEP

MW, Bx

-

-

-

N/A

N/A

Controlled

Xing et al. [11]

Cut, Musc

N/A

G, H

MW, ENMG, Bx

-

Yes

-

MTX, CyA

MTX 7.5 mg/week

Controlled

Kato et al. [12]

Cut, Musc, LA, Ab

ANA(+), Jo(-)

G, H, RP, MH, VS

MW, Bx

-

Yes

Yes

MP

N/A

Remission

Inkeles et al. [13]

Cut, Ab

ANA(+), sDNA(-), SSA(-), SSB(-), Sm(-), RNP(-), aCL(-), Scl70(-), ACA(-)

nonspecific interface

dermatitis with perivascular inflammation

-

-

-

-

AZA, MTX, MMF, CyA, RTX, HCQ, UST

CyA 5 mg/kg/day

Remission

Montoya et al. [14]

Cut, Musc

ANA(-), Jo(-), Mi2(-)

G, SP, PE

Bx, ENMG

-

-

-

RTX, MP

UST 45 mg/12week

CCR

Akiyama et al. [15]

Cut, Musc, Ab

ANA(+), SSA(+), TIF-1 g(+)

G, H, SS

MW, Bx

-

-

-

MTX, CyA, MMF, GC

MTX 6 mg/kg

CCR

Dicaro et al. [16]

Cut, Musc, LA

ANA(-), Scl70(-)

G, SP

Bx

-

-

-

MTX, ADA

N/A

CCR

Kim et al. [17]

Cut, Musc

N/A

G, H

MW, Bx, MRI

-

-

-

MP

MTX

CCR

Cut, Musc, LA

N/A

G, H

MW

-

-

-

MTX, MMF, CyA

MMF 20 mg/kg, CP (80-100 mg/mL

CCR

Cut

N/A

G, H

MW, MRI, Bx

-

-

-

MTX

MTX 25 mg/m2/week

CCR

Machado et al. [18]

Bohan & Peter

ANA(+), ENA(-)

Typical rash

MW, Bx

-

-

Yes

CyA

CYC 150 mg/day

Activity

Gran et al. [19]

Cut, Musc

ANA(-), MSA(-)

G, H, VS

MW, MRI

Yes

-

Yes

AZA

MP 1 g

Activity

Pavlovic et al. [20]

Cut, Musc, LA

N/A

G, SP

MW, Bx. ENMG

-

-

-

AZA, MP

Aza 2 mg/kg/day

Remission